Posterior Capsular Fibrosis Rates Of Vivity®, Isopure® And Eyhance®: A Prospective, Double-Blind, Randomised Comparison Between Three Hydrophobic Enhanced Depth-Of-Focus Intraocular Lenses

To evaluate the rates of posterior capsular fibrosis (PCO) in patients implanted with Vivity® , Isopure® , or Eyhance® IOLs.

This substudy is part of a double-blind, randomized, prospective trial programme conducted at Vista Alpina Eye Clinic, Visp, Switzerland, involving 280 eyes of 140 patients. Each patient received bilateral implants of Vivity®, Isopure®, or Eyhance®, targeting mini-monovision (-0.5D).

We assessed the rates of YAG-laser treatments and the presence of significant PCO in non-YAG-treated patients 4-6 months post-surgery.

• YAG Rates: Eyhance® showed the lowest YAG rate at 0%, followed by Vivity® at 16.2%, and Isopure® at 20.5% (p=0.003).
• Combined YAG and PCO Rates: Eyhance® again had the lowest combined rate at 4.0%, followed by Vivity® at 16.2%, and Isopure® at 25.0% (p=0.005).

These findings highlight significant differences in the incidence of PCO and the subsequent need for YAG laser treatment across the different IOL types, despite all being made of hydrophobic acrylic material with a square-edge design. Notably, the highest PCO rates were observed with Isopure® (water content around 4%), the lowest with Eyhance® (water content <1%), and Vivity® displaying intermediate rates (water content around <0.5%). This suggests that even a low water content in hydrophobic material may influence PCO formation and YAG-laser treatment rates, emphasizing the need for tailored IOL selection based on individual patient needs and lens properties.